Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer. A phase II study of anlotinib plus albumin-bound paclitaxel in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results